Worth reading
66In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
20000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the 18th Stock Acquisition Rights issued through a third-party allotment (with provisions for adjustment of the exercise price and suspension of exercise)
Who receives how much
Shares delivered during the month under review: 20,000 shares (20,000 new shares and 0 treasury shares transferred)
EVO FUND (the allottee at the time of issuance on 4 December 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio subject to the exercise restriction: 0.7% (20,000 shares / 2,950,228 shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥451, ¥448, ¥441, ¥431, ¥424, ¥421 and ¥417 (with provisions for adjustment of the exercise price)
Number of Stock Acquisition Rights
Total issued: 10,000 Stock Acquisition Rights; unexercised as of the end of the month preceding the relevant month: 7,400; unexercised as of the end of the relevant month: 7,200
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Timing 4 December 2025 / Type Issuance through a third-party allotment of the 18th and 19th Stock Acquisition Rights (with provisions for adjustment of the exercise price and suspension of exercise) / Amount Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the 18th Stock Acquisition Rights issued through a third-party allotment (with provisions for adjustment of the exercise price and suspension of exercise) |
| Number of shares to be issued or disposed of | Shares delivered during the month under review: 20,000 shares (20,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (the allottee at the time of issuance on 4 December 2025) |
| Dilution Rate | Exercise ratio subject to the exercise restriction: 0.7% (20,000 shares / 2,950,228 shares) |
| Total number of issued shares | 3,210,228 shares (as of the end of the month preceding the relevant month, including 3,616 treasury shares) → Not disclosed |
| Exercise price | Exercise prices during the month: ¥451, ¥448, ¥441, ¥431, ¥424, ¥421 and ¥417 (with provisions for adjustment of the exercise price) |
| Number of Stock Acquisition Rights | Total issued: 10,000 Stock Acquisition Rights; unexercised as of the end of the month preceding the relevant month: 7,400; unexercised as of the end of the relevant month: 7,200 |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Timing 4 December 2025 / Type Issuance through a third-party allotment of the 18th and 19th Stock Acquisition Rights (with provisions for adjustment of the exercise price and suspension of exercise) / Amount Not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is a report on the monthly exercise status, and the company has provided no explanation of the reasons for the exercises.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.